有症状非复杂性憩室病患者接受利福昔明治疗后肠道微生物群及相关电子多感官系统变化数据集

数据集获取（Figshare）

• 源站标题：Data_Sheet_1_Gut Microbiota and Related Electronic Multisensorial System Changes in Subjects With Symptomatic Uncomplicated Diverticular Disease Undergoing Rifaximin Therapy.docx
• DOI：10.3389/fmed.2021.655474.s001
• 发布日期：2021-07-19
• 文件数：1 个
• 文件总体积：21.94 MB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Data_Sheet_1_Gut_Microbiota_and_Related_Electronic_Multisensorial_System_Changes_in_Subjects_With_Symptomatic_Uncomplicated_Diverticular_Disease_Undergoing_Rifaximin_Therapy_docx/15001527

命令行下载

curl -L -o "Data_Sheet_1_Gut Microbiota and Related Electronic Multisensorial System Changes in Subjects With Symptomatic Uncomplicated Diverticular Disease Under.docx" "https://ndownloader.figshare.com/files/28874334"

文件清单

• Data_Sheet_1_Gut Microbiota and Related Electronic Multisensorial System Changes in Subjects With Symptomatic Uncomplicated Diverticular Disease Under.docx（21.94 MB）

文件总体积 21.94 MB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Background: Intestinal dysbiosis might play a pathogenetic role in subjects with symptomatic uncomplicated diverticular disease (SUDD), but the effect of rifaximin therapy has been scantly explored with regard to gut microbiota variations in patients with SUDD.
Aims: To verify to which extent rifaximin treatment affects the gut microbiota and whether an electronic multisensorial assessment of stools and breath has the potential for detecting these changes.
Methods: Breath and stool samples were collected from consecutive patients with SUDD before and after a 7 days’’ therapy with rifaximin. Stool microbiota was assessed, and the electronic multisensorial assessment was carried out by means of the BIONOTE electronic (e-)tongue in stools and (e-)nose in breath.
Results: Forty-three subjects (female 60%, median age 66 years) were included, and 20 (47%) reported clinical improvement after rifaximin therapy. Alpha and beta diversity of stool microbiota did not significantly change after treatment, while a significant variation of selected taxa was shown (i.e., Citrobacter, Coprococcus, Anaerotruncus, Blautia, Eggerthella lenta, Dehalobacterium, SMB53, and Haemophilus parainfluenzae). Overall, the electronic multisensorial system suboptimally mirrored microbiota changes, but it was able to efficiently predict patients’’ clinical improvement after rifaximin with accuracies ranging from 0.81 to 0.98.
Conclusions: In patients with SUDD, rifaximin administration is associated with significant variation of selected taxa. While inaccurate in predicting gut microbiota change, an electronic multisensorial system, made up of e-tongue and e-nose, was able to predict clinical improvement, thus potentially qualifying as an easy and cheap tool to forecast subjects taking most likely benefit from rifaximin therapy.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fmed.2021.655474.s001（source: https://frontiersin.figshare.com/articles/dataset/Data_Sheet_1_Gut_Microbiota_and_Related_Electronic_Multisensorial_System_Changes_in_Subjects_With_Symptomatic_Uncomplicated_Diverticular_Disease_Undergoing_Rifaximin_Therapy_docx/15001527）。